In acquiring Amunix, Sanofi becomes the latest big pharmaceutical company to strike a deal to gain access to technology that improves the safety and efficacy of T cell engager cancer therapies. Sanofi agreed to pay $1 billion up front to buy preclinical Amunix.
Specialty drugs represent a growing share of overall pharmaceutical sales, and Omnicell is acquiring specialty pharmacy technologies company ReCept Pharmacy to enter this market. Omnicell is paying $100 million cash to buy ReCept.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
ChemoCentryx has spent decades developing oral alternatives to injectable and infused biologic drugs that treat chronic autoimmune conditions. The research finally paid off with FDA approval of Tavneos, a ChemoCentryx pill for a rare autoimmune disease.
The startup, which says it uses “digital twins” to help people manage their diabetes, recently raised a series C round led by ICONIQ Growth. It uses data from connected devices, blood tests and consultations to come up with personalized recommendations.
The digital health startup received FDA clearance for its carbon monoxide sensor to be used for smoking cessation without oversight from a healthcare provider. The expanded indication came after Carrot submitted the results of a single-arm study claiming its device increased people’s motivation to quit smoking.
Medical device maker Dexcom is partnering with Livongo such that users of Livongo that have diabetes and use Dexcom's continuous glucose monitoring system can sync their data on the Livongo platform.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Both Livongo and Health Catalyst held their IPOs today and saw their stock price soar more than 40 percent in early trading.
The chronic disease management company filed its S-1 paperwork on Friday, joining Change Healthcare, Phreesia and Health Catalyst as part of the raft of companies planning to go public after a nearly three year IPO drought in digital health.
The company, which will be listed on the Nasdaq exchange under the ticker symbol "LVGO," offers tech-enabled solutions that help to monitor and manage people with chronic conditions like diabetes, hypertension and behavioral health issues.
With the new feature, members have the ability to link their Apple, Fitbit or Samsung smartwatches to the company's app to receive health information on their wrist and share activity information back with Livongo to better personalize activity and health suggestions.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Wheat Ridge, Colorado-based Lutheran Medical Center, which is part of SCL Health, is using Qventus' technology in the inpatient setting to better coordinate patient discharges.
Health IQ started selling policies in 2016 based on rewarding individuals living healthier lifestyles with lower life insurance rates.
Among the 360 participants over the age of 50 in the study, the company was able to drive an average of 4.3 percent body weight loss, which works out to an average of 4.4 kgs.
The Wall Street Journal reports that Mountain View, California-based Livongo has enlisted Morgan Stanley, Goldman Sachs Group Inc. and JPMorgan Chase & Co. as underwriters for an IPO that would value the company in excess of $1 billion.
Burke joined the Mountain View, California-based chronic disease management company late last year after spending more than two decades at EHR giant Cerner.